Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
8
×
detroit top stories
fda
8
×
indiana blog main
8
×
indiana top stories
ipo
8
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
cancer
novartis
startups
abbvie
allergan
biogen
clinical trials
crispr
eli lilly
glaxosmithkline
medical devices
What
bio
roundup
8
×
drugs
ipo
new
black
cancer
car
covid
diamond’s
fda
life
medicines
pharmaceutical
science
therapeutics
years
acquisitions
activity
allogene
announced
appetite
approvals
august
bails
biogen
biopharma
biotech
brand
bread
bridgebio
busy
butter
buyout
capital
cash
celgene
ceo
clamped
collabs
Language
unset
Current search:
fda
×
roundup
×
" detroit blog main "
×
ipo
×
" indiana blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More